Emily C L Wong Selected Research

Ustekinumab (CNTO 1275)

1/2024	Delayed Ustekinumab and Adalimumab Responders Have Similar Outcomes as Early Responders in Biologic-Naïve Crohn's Disease.
12/2023	Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
1/2023	Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's Disease.
1/2022	Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease.
1/2022	Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
10/2021	Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn's Disease: A Post-hoc Analysis.
1/2021	The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
1/2021	Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn's Disease: A Post Hoc Analysis of the IM-UNITI Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Emily C L Wong Research Topics

Disease

16	Crohn Disease (Crohn's Disease) 01/2024 - 01/2021
11	Ulcerative Colitis 03/2024 - 01/2022
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2023 - 01/2022
2	Ulcer 01/2023 - 01/2022
2	Necrosis 01/2023 - 01/2022
1	Hemorrhage 12/2023
1	Abdominal Pain (Pain, Abdominal) 10/2023
1	Eosinophilic Esophagitis 10/2023
1	Inflammation (Inflammations) 01/2023
1	Colonic Diseases 01/2022
1	Pathologic Constriction (Stenosis) 10/2021
1	Overweight 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 02/2020
1	Kidney Neoplasms (Kidney Cancer) 11/2019
1	Lymphatic Metastasis 10/2019

Drug/Important Bio-Agent (IBA)

9	Infliximab (Remicade)FDA Link 10/2023 - 10/2021
8	Ustekinumab (CNTO 1275)FDA Link 01/2024 - 01/2021
6	vedolizumabIBA 03/2024 - 01/2022
6	Adalimumab (Humira)FDA Link 01/2024 - 10/2021
4	Adrenal Cortex Hormones (Corticosteroids)IBA 10/2023 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 04/2023 - 03/2021
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2023 - 03/2021
2	tofacitinibIBA 01/2023 - 01/2023
1	mepolizumabIBA 10/2023
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2023
1	Interleukin-13 Receptors (Interleukin 13 Receptor)IBA 01/2023
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2023
1	ElementsIBA 01/2023
1	Oral ContraceptivesIBA 01/2023
1	Azathioprine (Imuran)FDA LinkGeneric 10/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2021

Therapy/Procedure

16	Therapeutics 03/2024 - 11/2019
3	Biological Therapy 01/2024 - 05/2022
1	Nephrectomy 11/2019
1	Lymph Node Excision (Lymph Node Dissection) 10/2019